T cell trafficking into tumors depends on a "match" between chemokine receptors on effector cells (e.g., CXCR3 and CCR5) and tumor-secreted chemokines. There is often a chemokine/chemokine receptor "mismatch", with tumors producing minute amounts of chemokines, resulting in inefficient targeting of effectors to tumors. We aimed to alter tumors VV.CXCL11 should be considered as a potential approach to augment adoptive T cell transfer or vaccine immunotherapy.
Introduction
Breaking tolerance to self-antigens has recently been achieved in some cancers with the use of antibodies to checkpoint inhibitors such as CTLA4 and PD-1 (1) (2) (3) . Unfortunately, only a small subset of patients respond to checkpoint inhibitors, and many who initially respond eventually relapse. Additional tactics are thus needed, especially strategies to generate, rather than just revitalize, anti-tumor T cells. Two approaches that are being actively pursued are vaccines and adoptive cell immunotherapy (ACT). ACT is the transfer of immune cells for the treatment of cancer or infectious disease. It is now possible to genetically engineer T cells to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) that target specific tumor cell surface antigens (4) .
Although the adoptive transfer of CAR T cells has demonstrated remarkable success in treating hematologic tumors, prominently, the use of CD19 CARs in leukemias (5) (6) (7) (8) , success in solid tumors has been much more limited. The reason for this difference is not yet known, and is likely multifactorial (9, 10), but one major limitation appears to be limited "trafficking"; that is, once an effector T cell or CAR T cell is infused into a patient or generated endogenously by a vaccine, an immediate obstacle is the ability of the T cells to successfully infiltrate the tumor.
T cell trafficking into tumors is dependent on the appropriate expression of adhesion receptors on both T cells and the tumor endothelium and on a "match" between the chemokine receptors on the effector T cells and the chemokines secreted by the tumors (11) . The chemokine receptors expressed at the highest levels on central or effector memory cells (which includes CAR T cells or vaccine-induced T cells) are CXCR3 and CCR5 (12, 13) . Effector T cells would [RANTES]). Unfortunately, there is often a chemokine/chemokine receptor "mismatch", with tumors producing very small amounts of RANTES or CXCR3 ligands, thus resulting in inefficient targeting of CXCR3 high CD8 + effectors to tumor sites (14) . For example, using a human CAR T cell model, we found that less than 1% of injected T cells entered subcutaneous tumors by 5 days (9).
One proposed approach to overcome this problem in genetically engineered T cells is to design cells that co-express "better-matched" chemokine receptors. For example, using mesothelioma tumors that make large amounts of CCL2, we demonstrated enhanced intratumoral migration of CAR T cells when they were engineered to co-express the CCR2 gene, thus leading to subsequent tumor eradication (12) . Similarly, others have shown that the use of GD2-CAR T cells co-expressing CCR2b exhibited improved trafficking and tumor control compared to GD2-CAR alone (15) . We have also recently found that the genetic inhibition of protein kinase A (PKA) activation in CAR T cells increased their ability to infiltrate tumors in vivo, in part due to higher baseline expression of CXCR3 (10).
There are some potential limitations of this approach, however. First, although tumors may secrete chemokines like CCL2 or IL-8, these chemokines are not tumor-specific. Second, some preliminary data suggest that chronic stimulation of T cells through a chemokine receptor like CCR2 leads to the continuous production of high levels of intracellular calcium which can result in accelerated T cell hypofunction (16, 17 An alternative approach to enhancing the chemokine/chemokine receptor "match" would be to alter the tumors to enable them to secrete chemokines like CCL5 or one of the IFN-induced CXCR3 ligands so that they could potentially attract effector T cells generated by vaccines or adoptive T cell transfer (13) . In this study, we explored two approaches to induce tumor secretion of the chemokine CXCL11 with the goal of augmenting immunotherapy. We chose CXCL11 since it potently attracts T cells into tumor sites, thereby enhancing anti-tumor effects via association with the receptor CXCR3 (18) (19) (20) . CXCL11 expression is also strongly induced by interferons and CXCL11 has been shown to bind CXCR3 with a higher affinity than other ligands such as CXCL9 or CXCL10 (21).
In our first approach, we used modified CAR T cells to serve as vehicles to deliver CXCL11 into the tumor. We have previously characterized a model in which human CAR T cells targeted to the tumor antigen mesothelin (mesoCAR T cells) injected intravenously into immunodeficient mice bearing treatment-resistant human tumors expressing mesothelin that enter the tumors in only very small numbers (9, 12) . Once there, they proliferate and slow tumor growth. However, the tumors are not eradicated, largely due to the loss of antitumor activity of the T cells over time. We reasoned that CAR T cells that produced CXCL11 could accumulate within the tumors and "reprogram" the tumor microenvironment, even if they became hypofunctional with regard to tumor cell killing. This could potentially attract more T cells sequestered in other organs from the original CAR T cell injection or enhance trafficking from a second injection of mesoCAR T cells, given 2 weeks after the first dose.
In our second approach, we utilized a modified oncolytic vaccinia virus (VV) that was engineered to produce CXCL11. Oncolytic vaccinia viruses (VVs) have been shown to (24) (25) (26) (27) . As an example, we reported enhanced anti-tumor efficacy with a VV (28, 29) . A VV expressing CCL5 has been used to enhance the efficacy of vaccines and cytokine-superactivated T cells (30) . Similarly, the use of an oncolytic adenoviral vector expressing CCL5 combined with GD2-CAR T cells robustly controlled neuroblastoma progression in mice and improved CAR T cell influx (31) . Recently, a VV expressing CXCL11 was shown to increase the numbers of endogenous CD8 T cells in specific murine tumors (32, 33) . Accordingly, we combined the use of a VV producing CXCL11 with mesoCAR T cells and with an anti-tumor vaccine.
Results

CAR/CXCL11 T cell studies
Human T cells expressing either a CAR targeting mesothelin (mesoCAR) or the CAR plus the human CXCL11 gene (mesoCAR/CXCL11) were generated (Suppl. Fig. 1 ). After 10 days, expression of the CAR by flow cytometry was 40-50% for both of the T cell types (Suppl Fig. 2 ).
Supernatant from the T cell cultures were analyzed for CXCL11 concentrations by ELISA and showed high levels of secretion of CXCL11 by the CAR/CXCL11 T cells (Fig. 1A) .
Supernatant from the T cells was also used to test the chemoattraction of activated human T cells in a migration assay. Compared to cell media as a negative control, conditioned media from the CAR/CXCL11 cells significantly enhanced migration of human T cells to a degree similar to that of 10 ng/ml of recombinant human CXCL11 protein used as a positive control (Fig. 1B) . .5% in the CAR/CXCL11 spleens (P < 0.02) (Suppl. Fig. 3 ). Given the lack of enhanced anti-tumor efficacy by delivering CXCL11 via CAR T cells, we studied a second delivery approach using a recombinant oncolytic vaccinia virus (VV) modified to secrete CXCL11. We hypothesized that this approach might have some efficacy due to direct oncolytic effects, but would also serve to augment trafficking of adoptive transfer of T cells or endogenous generation of anti-tumor T cells using a vaccine. Thus, in these studies, we utilized a fully murine system and a VV that secreted murine CXCL11.
VV.CXCL11 Studies
VV.CXCL11 particles are able to replicate and kill lung cancer cells in vitro while producing high levels of CXCL11
To evaluate the replicative potential and killing ability (and therefore, oncolytic capability) of VV.CXCL11 in culture, we infected murine TC1 lung cancer cells at a MOI of 1.
Cell supernatants and lysates were collected at various time points, and titered using a standard plaque protocol. VV.CXCL11 replicated and killed TC1 cells efficiently in a time-dependent manner (Suppl. Fig 4A) . The in vitro cytolytic effect of our control (VV.luc) and CXCL11-producing vaccinia vectors 48 hours post-TC1 infection was identical (Suppl. Fig. 4B ). Since this virus vector expresses CXCL11, we performed ELISA assays to detect CXCL11 secretion at differing MOIs. As expected, CXCL11 secretion intensified with increasing MOI (Suppl. Fig.   4C ). The proliferation of two viruses in TC1 cells was also very similar (Suppl. Fig 4D) .
Intravenous administration of VV.CXCL11 induces generation of CXCL11 in vivo and results in modest anti-tumor control
We next determined if VV.CXCL11 was able to control tumor progression in vivo. Wild in homogenized tumor tissue (Fig. 3C ). However, we did not detect differences in the levels of other chemokines in treated TC1 tumors, indicating that CXCL11 was specifically produced in this model (Fig. 3D) .
The combinatorial administration of intravenous VV.CXCL11 and the E7 cancer vaccine elicits robust anti-tumor control and heightened influx of T cells into tumor sites
Although the intravenous administration of these vaccinia vectors had only a modest effect on tumor growth, presumably due largely to their oncolytic effects, we did observe a twofold increase in endogenous CD8 TIL influx (Fig. 3B) progression to a superior and statistically significant (P < 0.05) extent compared to the other treatment groups (Fig. 4A) . Survival was also significantly longer in the animals treated with the combination (Fig. 4B) . Ex vivo TIL analysis using flow cytometry revealed a significantly higher influx of CD3 + T cells (Fig. 4C) . We also examined the % of T cells that were antigen specific by staining the CD8 T cells with an HPV-E7-specific tetramer. In tumors from mice that were untreated or treated with VV.luc or VV.CXCL11, the percent of tetramer + cells was less than 2% (Suppl. Fig. 5 ). Treatment with the vaccine alone or with VV.luc and vaccine resulted in an increase of intra-tumoral tetramer + cells to about 4%, however, the percent of tetramer + cells was significantly higher (12.4%; P < 0.05) in the tumors from mice treated with vaccine plus VV.CXCL11 (Fig. 4D) .
Intravenous VV.CXCL11 significantly augments mesoCAR immunotherapy
We next examined the ability of VV.CXCL11 to enhance the efficacy of mesoCAR adoptive immunotherapy in mice bearing mesothelin-transduced TC1 tumors (TC1-meso).
Mice (n = 5 per group) bearing TC1-meso tumors were left untreated, intravenously injected with 10 8 pfu VV.CXCL11 on Day 6, intravenously injected with 10 7 mesothelin CAR-expressing T cells on day 8, or given both the VV.CXCL11 on Day 6 and mesoCAR T cells intravenously on Day 8. As shown in Fig. 5A , both single treatments significantly (P < 0.05) reduced tumor size compared to control mice, however the combination was significantly (P < 0.05) more effective than either treatment alone. Tumors were digested and analyzed by flow cytometry on Day 22. Consistent with Fig. 3B , the % of digested tumor cells that were CD3+ T cells was significantly higher in both groups receiving VV.CXCL11 (Fig. 5B) . Because the numbers of tumors that was more than double than that seen in the tumors treated with mesoCAR T cells alone (P < 0.05) (Fig. 5C ).
To demonstrate the specificity of the CXCL11 transgene in this effect, we repeated the animal experiment, but added groups that received iv VV.luc alone and iv VV.luc plus iv mesoCAR T cells. Whereas the combination of mesoCAR T cells plus VV.CXCL11 was again significantly better (P < 0.05) than all other treatments, administration of VV.luc did not augment the efficacy of mesoCAR T cells (Fig. 5D ).
Discussion
After intravenous injection, oncolytic VVs can enter tumors where they directly kill a proportion of tumor cells, and at the same time, alter the tumor microenvironment, inducing the production of many types of inflammatory cytokines (24-26, 28, 29) . Although this induction of inflammation is usually detrimental to viral spreading, it has become increasingly recognized that this activation of the immune system can also trigger anti-tumor immunologic responses (22, 27) . This VV-induced inflammation can be further manipulated by the introduction of specific cytokine genes into the VV genome. The most successful of the vaccinia vectors in clinical trials expresses the cytokine GM-CSF which is thought to attract dendritic cells and trigger anti-tumor immunity (24) (25) (26) . Our group has introduced the type 1 interferon, interferonvector for reasons of safety and increased efficacy (28, 29) . In our study, which used intravenous injection of VV.CXCL11, we could also demonstrate marked increases in intratumoral levels of CXCL11 (Fig. 3C ) along with increased number of total T cells (Fig. 3B) . In our subcutaneous model, the VV.CXCL11 was not more efficacious than the control VV (Fig. 3A) . The reasons for this difference with previous studies is not known for certain, however, since the two studies used different tumor lines, there are possible differences in the levels of endogenous immunogenicity of the tumors, the strains of mice used, and likely in the degree of replication of the virus. In the Liu paper (32), the authors used the AB12 mesothelioma tumor which grows in Balb/C mice and is quite an immunogenic Our other approach was based on the idea of using CAR T cells as vehicles to deliver a chemokine into the tumor (41). This idea was pioneered in studies where production of the cytokine interleukin-12 (IL12) by CAR T cells appeared to enhance their efficacy in murine models (41, 42) . This approach resulted in some toxicity in the first human trial using TILs (8), but additional studies using CD19-IL-12 CARs are underway. We postulated that secretion of CXCL11 by CAR T cells might also enhance efficacy. However, in contrast to our studies using VV.CXCL11, we were not able to enhance T cell trafficking or anti-tumor efficacy, and, in fact, when compared in a "head-to-head" fashion after one injection, the CAR/CXCL11 T cells performed much more poorly than the control CAR T cells ( Fig. 2A) . We have not comprehensively explored the reasons for this, but have a number of possible explanations. It appears that the CAR-CXCL11 T cells were able to make relatively large amounts of CXCL11 Fig. 1) . Although that did not affect our ability to expand the cells after transduction (data not shown), when we studied the ability of the CAR-CXCL11 T cells in vitro, we noted a clear decrement (~30%) in their ability to kill tumor cells compared to control CAR T cells (Fig. 1D) .
Whereas normal chemokine/chemokine receptor signaling is relatively transient and accompanied by rapid downregulation of the CCR, we think we may have perturbed this situation by the unabated secretion of chemokine. Since CCR signaling involves increases in intracellular calcium and chronic calcium signaling can lead to T cell anergy (16, 17), we think it is likely that the presence of chronic chemokine stimulation (or high levels of transduced CCRs (see above)) leads to enhanced T cell hypofunction, explaining their poor killing ability in vivo.
It is possible that a lower level of CXCL11 secretion might have led to less hypofunction, however, since the expression of the CAR was linked to that of CXCL11, we did not have an easy way to "titrate" the level of CXCL11 secretion in our T cells.
We had hoped that the first "wave" of injected CAR T cells would start to produce CXCL11 which would then help to attract CAR T cells that were injected subsequently.
Unfortunately, the opposite occurred, with fewer CAR T cells visualized in the mice that received CAR-CXCL11 followed by CAR T cells. In addition to inducing T cell hypofunction, another possible problem with having chronic, relatively high levels of CXCL11 in the tumor is the known ability of CXCL11 to inhibit angiogenesis (43) . Alterations in the tumor blood vessels might have inhibited the trafficking of the second dose of injected T cells explaining the low numbers of T cells we observed in the tumors (but not spleens).
Regardless of the reasons, our data clearly favor the approach using the vaccinia virus to deliver CXCL11. Our study suggests that the transient intra-tumoral pulse of CXCL11 as Enhancing T cell tumor trafficking with a VV-CXCL11 could also be used in other types of immunotherapies (dendritic cell vaccines, checkpoint inhibitors, etc.) to enhance efficacy.
Materials and Methods
Creation of the CXCL11-expressing CAR
The CXCL11 gene was ordered from Integrated DNA Technologies with 5' XbaI and 3'
BspeI flanking restriction enzyme sites. The CXCL11 gene was subcloned into a bicistronic lentiviral expression plasmid driven by the EF1a (eukaryotic translation elongation factor 1 alpha) promoter to be co-expressed with our mesoCAR (Suppl Fig 1) . The SS1BBz mesoCAR design has been previously described (34). Human CD4 and CD8 T cells acquired from the healthy donors were activated in vitro with anti-CD3/CD28 microbeads and were transduced with high-titer lentivirus encoding SS1BBz or SS1BBz/CXCL11. After 10 days, expression of SS1BBz by flow cytometry was 40-50% for each of the T cell types (Suppl Fig. 2 ).
Cell lines and animals
The EMMeso human malignant mesothelioma cell line was generated from a mesothelioma pleurectomy specimen. Loss of mesothelin expression on the parental cell line (EMP) occurred in culture. Thus, EMP was transduced to stably express high levels of mesothelin to produce the EMMeso cell line. These lines were also transduced to stably express green fluorescent protein (GFP) and firefly luciferase (ff-luc) (12) . TC1 murine lung cancer cells and Use Committee (IACUC) at the University of Pennsylvania. Pathogen-free wild-type C57Bl/6 (strain CD45.2) mice were obtained from Charles River Laboratories. All test animals used were females used at 10-12 weeks of age.
Viruses
The vaccinia virus vector background is vvDD which as deletions in the VGF and TK viral genes (32) . The VV expressing firefly luciferase (VV.luc), or firefly luciferase and murine CXCL11 (VV.CXCL11) were generated as previously described (32) . The replicative potential of these viruses in vitro using TC1 murine lung cancer cells was assessed as using a standard plaque assay protocol (29, 32) . In vivo, TC1 tumors were dissected from mice treated with these virus vectors, and processed as described (29) . The generation of CXCL11 and other cytokines was measured using standard ELISA assays (29) . The use of the E7 cancer vaccine, as delivered by an adenoviral vector (Ad.E7) was previously established by our group (37).
Generation of CAR T cells
Human T cells were transduced with lentiviruses expressing the mesothelin CAR or mesothelin-CXCL11 CAR as previously described (9, 12) . Expression levels averaged between 40-70% (Supp. Figure 2) . To produce murine cells expressing CAR construct targeting human mesothelin (mesoCAR), the mesothelin-CAR construct was subcloned into the retroviral MigR1 backbone also expressing GFP; primary murine T cells were isolated and transduced with these retroviral particles as previously described (36) . Expression levels averaged between 50-70%. 
Flow cytometry analysis
After harvesting, tumors were digested as previously described (29, 37) . 
In vivo tumor studies in immunodeficient mice
-chain Knockout (NSG) mice that were bred at the University of Pennsylvania as described (9, 12) . 
Statistical analyses
All results were reported as means ± SEM. For studies comparing 2 groups, the Student's t test was used, while for studies comparing more than 2 groups, one-or two- 
